May 29, 2015
British Columbia Securities Commission
Alberta Securities Commission
The Manitoba Securities Commission
Ontario Securities Commission
Nova Scotia Securities Commission
Via Sedar
NOTICE PURSUANT TO SUBSECTION 11.3 OF
NATIONAL INSTRUMENT 51-102 (“NI 51-102”)
CONTINUOUS DISCLOSURE OBLIGATIONS
Pursuant to the requirements set out in subsection 11.3 of NI 51-102, the undersigned hereby gives notice of the results of voting from the May 27, 2015 Annual Meeting of Shareholders of Trillium Therapeutics Inc.
1. | Election of Directors |
The shareholders of the Corporation voted to elect the following individuals as directors of the Corporation until the next annual meeting of shareholders or until their successors are elected or appointed, as follows:
Name | For | % For | Withheld | % Withheld |
Luke Beshar | 3,123,913 | 99.66 | 10,695 | 0.34 |
Henry Friesen | 3,131,370 | 99.90 | 3,238 | 0.10 |
Robert Kirkman | 2,874,070 | 91.69 | 260,538 | 8.31 |
Michael Moore | 3,131,370 | 99.90 | 3,238 | 0.10 |
Thomas Reynolds | 3,124,071 | 99.66 | 10,537 | 0.34 |
Niclas Stiernholm | 3,131,370 | 99.90 | 3,238 | 0.10 |
Calvin Stiller | 3,131,370 | 99.90 | 3,238 | 0.10 |
2. | Appointment of Auditors |
The shareholders of the Corporation voted, on a show of hands, to appoint Ernst& Young LLP, Chartered Accountants, as the auditor of the Company until the close of business at the next annual general meeting of shareholders, at a remuneration to be fixed by the Directors.